Get started
Author

Chunxiao Wang

Observed institution: Eli Lilly (United States)
ORCID: 0009-0007-2877-2247
Observed ORCID: 0009-0007-2877-2247
OpenAlex ID: A5113060502
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma
2023 · Michael L. Wang, Wojciech Jurczak, et al. · Journal of Clinical Oncology · 121
PDF
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study
2024 · William G Wierda, Nirav N Shah, et al. · The Lancet Haematology · 40
Pirtobrutinib in Richter Transformation: Updated Efficacy and Safety Results with 18-Month Median Survival Follow-up from the Phase 1/2 BRUIN Study
2023 · William G. Wierda, Nirav N. Shah, et al. · Blood · 11
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia
2025 · Jennifer R. Brown, Bastien Nguyen, et al. · Blood · 8
PDF
Ramucirumab for patients with intermediate-stage hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): Pooled results from two phase III studies (REACH and REACH-2).
2020 · Masatoshi Kudo, Richard S. Finn, et al. · Journal of Clinical Oncology · 7
Association Between Neutrophil Percentage to Serum Albumin Ratio and in-Hospital Mortality of Patients with Chronic Obstructive Pulmonary Disease in Intensive Care Unit: A Retrospective Cohort Study
2025 · Yanfei Shi, Yushan Shi, et al. · International Journal of COPD · 5
PDF
Fixed-Duration Pirtobrutinib Combined with Venetoclax ± Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results, Including MRD Data, from the BRUIN Phase 1b Study
2023 · Lindsey E. Roeker, Jennifer A. Woyach, et al. · Blood · 5
Long-term safety with ≥12 months of pirtobrutinib in relapsed/refractory (R/R) B-cell malignancies.
2023 · Catherine Callaghan Coombs, Nirav Niranjan Shah, et al. · Journal of Clinical Oncology · 4
P1087: Pirtobrutinib in Covalent Btk-inhibitor Pre-treated Mantle Cell Lymphoma: Updated Results and Subgroup Analysis From the Phase 1/2 Bruin Study With >3 Years Follow-up From Start of Enrollment
2023 · Wojciech Jurczak, Pier Luigi Zinzani, et al. · HemaSphere · 3
Pirtobrutinib in covalent BTK-inhibitor (cBTKi) pre-treated mantle cell lymphoma (MCL): Updated results and subgroup analysis from the phase 1/2 BRUIN study with >3 years follow-up from start of enrollment.
2023 · Nirav Niranjan Shah, Wojciech Jurczak, et al. · Journal of Clinical Oncology · 2
Gut-heart axis disruption and LPS translocation: driving atrial fibrillation through inflammatory storm and fibrotic mechanisms
2026 · Chunxiao Wang, Zili Xu, et al. · Frontiers in Endocrinology · 1
PDF
Qilianshupi Decoction Alleviate Epithelial-mesenchymal Transition to Treat Chronic Atrophic Gastritis
2025 · Mengyi Shen, Chunxiao Wang, et al. · Combinatorial Chemistry & High Throughput Screening · 1
MCL-155 Pirtobrutinib in Covalent BTK Inhibitor Pre-Treated Mantle Cell Lymphoma: Updated Results and Subgroup Analysis from the Phase 1/2 BRUIN Study With >3 Years Follow-Up from Start of Enrollment
2023 · Michael L. Wang, Nirav N. Shah, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
PDF
CT-166 Long-Term Safety With ≥12 Months of Pirtobrutinib in Relapsed/Refractory B-Cell Malignancies
2023 · Catherine E. Muehlenbein, Catherine C. Coombs, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
PDF
PO 73 Efficacy And Safety Of Pirtobrutinib in Adults with Immune Thrombocytopenia: A Phase 1/2 Dose-Finding Study in Progress
2026 · Tomás José González-López, Catherine Broome, et al. · Research and Practice in Thrombosis and Haemostasis
Qihuang Zhuyu Formula Attenuates Myocardial Ischemia Reperfusion Injury by Regulating Autophagy via the NF-κB P65/TRAIL Pathway
2026 · Siyuan Yin, Manlu Fan, et al. · Combinatorial Chemistry & High Throughput Screening
POSTER: MCL-155 Pirtobrutinib in Covalent BTK Inhibitor Pre-Treated Mantle Cell Lymphoma: Updated Results and Subgroup Analysis from the Phase 1/2 BRUIN Study With >3 Years Follow-Up from Start of Enrollment
2023 · Michael L. Wang, Nirav N. Shah, et al. · Clinical Lymphoma Myeloma & Leukemia
PDF
POSTER: CT-166 Long-Term Safety With ≥12 Months of Pirtobrutinib in Relapsed/Refractory B-Cell Malignancies
2023 · Catherine E. Muehlenbein, Catherine C. Coombs, et al. · Clinical Lymphoma Myeloma & Leukemia
PDF
P618: Long-term Safety With ≥12 Months of Pirtobrutinib in Relapsed/refractory (r/r) B-cell Malignancies
2023 · Wojciech Jurczak, Catherine C. Coombs, et al. · HemaSphere
Works count: 19
Citation count: 210
H-index: 5
I10-index: 3
Year
Topic
Type